372
Views
14
CrossRef citations to date
0
Altmetric
Report

Screening of the TBK1 gene in familial and sporadic amyotrophic lateral sclerosis patients of Chinese origin

, , , , , , , & show all
Pages 605-607 | Received 09 Feb 2016, Accepted 28 Mar 2016, Published online: 03 Jun 2016
 

Abstract

TANK-binding kinase 1 (TBK1) has been recently identified as a risk gene of amyotrophic lateral sclerosis (ALS). The aim of this study was to assess the contribution of TBK1 mutations to Chinese ALS patients. We sequenced the coding regions of TBK1 in a cohort of Chinese ALS patients, including 271 sporadic ALS patients and 23 familial ALS patients. Two potentially pathogenic mutations, L62P and I334T, were identified in two independent sporadic ALS patients, accounting for 0.7% of total ALS cases. Both mutations were absent from our 384 healthy controls and public single nucleotide polymorphisms databases. In conclusion, we propose that TBK1 is not a frequent causal gene in Chinese ALS patients.

Acknowledgements

The authors wish to thank all patients with ALS and all other individuals who volunteered blood samples for this study. This study was supported by the National Natural Science Foundation of China (NSFC) and the Beijing Municipal Science and Technology Commission.

Declaration of interest

The authors declare no conflicts of interest.

Supplementary material available online

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.